Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAUL R MENA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1609892256
CMS profile
118905
Location
BURBANK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$165.85

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $165.85 10

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $50.27 4
Amgen Inc. $40.36 2
Seattle Genetics, Inc. $20.46 1
AstraZeneca Pharmaceuticals LP $19.08 1
Astellas Pharma US Inc $18.58 1
Genentech USA, Inc. $17.10 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAUL R MENA

NPI 1609892256 · CMS profile ID 118905

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BURBANK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609892256?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609892256?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609892256?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAUL R MENA, NPI 1609892256, CMS profile ID 118905, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1609892256?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $165.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $7.3911/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673675875 CMS
Amgen Inc. $21.7510/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662906021 CMS
PFIZER INC. $18.0808/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672553757 CMS
Genentech USA, Inc. $17.1008/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681394243 CMS
Astellas Pharma US Inc $18.5808/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655688845 CMS
Seattle Genetics, Inc. $20.4607/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678805349 CMS
Amgen Inc. $18.6105/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662906025 CMS
PFIZER INC. $8.5505/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672124867 CMS
PFIZER INC. $16.2503/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671903707 CMS
AstraZeneca Pharmaceuticals LP $19.0802/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685309735 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $165.85 10
PY2021 $62.94 6
PY2022 $44.07 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $175.09 1
PY2024 Principal investigator $3,280.00 3
PY2023 Principal investigator $10,185.60 2
PY2022 Recipient $6,880.00 1
PY2022 Principal investigator $325,752.17 18
PY2021 Recipient $18.75 1
PY2021 Principal investigator $395,903.61 24
PY2020 Recipient $1,784.80 2
PY2020 Principal investigator $859,478.43 105
PY2019 Recipient $4,319.40 2
PY2019 Principal investigator $2,023,210.35 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $31.64 12/31/2019 Non-covered Recipient Entity
Innovative Clinical Research Institute
A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN No dispute reported 06/30/2026 685000353
Principal investigator 1 TESARO, Inc. $66,906.00 12/26/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689414609
Principal investigator 1 TESARO, Inc. $66,906.00 12/03/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689414329
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 11/29/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691511237
Principal investigator 1 TESARO, Inc. $53,524.80 11/21/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689414219
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $333.45 11/20/2019 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 673114813
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 11/11/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691517729
Principal investigator 1 TESARO, Inc. $40,143.60 11/06/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689414039
Principal investigator 1 TESARO, Inc. $26,762.40 10/30/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689413879
Principal investigator 1 TESARO, Inc. $40,404.86 10/17/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689413651
Principal investigator 1 TESARO, Inc. $28,747.80 10/17/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689413657
Principal investigator 1 TESARO, Inc. $66,906.00 10/07/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689413425
Principal investigator 1 TESARO, Inc. $53,524.80 09/19/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689413131
Principal investigator 1 Merck Sharp & Dohme Corporation $421.02 09/13/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 691431733
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 09/13/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC No dispute reported 06/30/2026 691458371
Principal investigator 1 Merck Sharp & Dohme Corporation $338.22 09/13/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC No dispute reported 06/30/2026 691458375
Principal investigator 1 Merck Sharp & Dohme Corporation $400.26 09/13/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC No dispute reported 06/30/2026 691458379
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 09/13/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 691461439
Principal investigator 1 Merck Sharp & Dohme Corporation $462.48 09/13/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 691461619
Principal investigator 1 TESARO, Inc. $40,143.60 09/03/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412955
Principal investigator 1 Merck Sharp & Dohme Corporation $1,514.53 08/27/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC No dispute reported 06/30/2026 691361599
Principal investigator 1 Merck Sharp & Dohme Corporation $1,113.55 08/27/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691390913
Principal investigator 1 TESARO, Inc. $93,668.40 08/14/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412651
Principal investigator 1 TESARO, Inc. $9,360.00 08/13/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS No dispute reported 06/30/2026 689412647
Principal investigator 1 TESARO, Inc. $22,360.50 08/08/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412553
Principal investigator 1 TESARO, Inc. $25,807.00 08/06/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412493
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 07/24/2019 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 691371611
Principal investigator 1 TESARO, Inc. $53,873.14 07/16/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412209
Principal investigator 1 TESARO, Inc. $10,854.90 07/16/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412235
Principal investigator 1 TESARO, Inc. $9,304.20 07/16/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412259
Principal investigator 1 TESARO, Inc. $80,673.34 07/16/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412271
Principal investigator 1 TESARO, Inc. $66,906.00 07/11/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412159
Principal investigator 1 Merck Sharp & Dohme Corporation $15,568.00 06/26/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691360025
Principal investigator 1 TESARO, Inc. $66,906.00 06/18/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411759
Principal investigator 1 TESARO, Inc. $33,800.40 06/11/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411709
Principal investigator 1 TESARO, Inc. $66,906.00 05/30/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411599
Principal investigator 1 TESARO, Inc. $138,826.94 05/14/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411319
Principal investigator 1 TESARO, Inc. $74,593.58 05/10/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411219
Principal investigator 1 TESARO, Inc. $66,906.00 05/08/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411199
Principal investigator 1 Eli Lilly and Company $14,624.00 04/29/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A PHASE 2 STUDY OF LY2784544 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS No dispute reported 06/30/2026 654292419
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 04/23/2019 Non-covered Recipient Entity
UNAVAILABLE
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive TPS 50 No dispute reported 06/30/2026 691386015
Principal investigator 1 TESARO, Inc. $66,906.00 04/17/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410911
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $333.45 04/12/2019 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 673113037
Principal investigator 1 PFIZER INC. $14,400.00 04/04/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEMSOUTHERN CALIFORNIA
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 671627611
Principal investigator 1 TESARO, Inc. $53,524.80 04/04/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410771
Principal investigator 1 Merck Sharp & Dohme Corporation $230.40 03/25/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691342871
Principal investigator 1 TESARO, Inc. $13,682.00 03/19/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410481
Principal investigator 1 TESARO, Inc. $66,906.00 03/06/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410361
Principal investigator 1 TESARO, Inc. $23,654.70 02/14/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410073
Principal investigator 1 TESARO, Inc. $66,906.00 02/14/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410151
Principal investigator 1 Eli Lilly and Company $23,674.00 02/12/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654297191
Principal investigator 1 TESARO, Inc. $51,801.10 02/12/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689410005
Principal investigator 1 Genentech, Inc. $31,149.00 02/05/2019 Non-covered Recipient Entity
PROVIDENCE TARZANA MEDICAL CENTER
PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC No dispute reported 06/30/2026 681086513
Principal investigator 1 TESARO, Inc. $66,906.00 01/29/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689409897
Recipient Eli Lilly and Company $489.40 01/28/2019 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654283541
Principal investigator 1 Merck Sharp & Dohme Corporation $15,805.00 01/17/2019 Non-covered Recipient Entity
UNAVAILABLE
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive TPS 50 No dispute reported 06/30/2026 691308935
Recipient Eli Lilly and Company $3,830.00 01/15/2019 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654283539
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $333.45 01/11/2019 Non-covered Recipient Entity
Providence Health System Southern Ca
PCYC-1145-LT No dispute reported 06/30/2026 673112939
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,500.00 01/09/2019 Non-covered Recipient Entity
Providence Little Company Of Mary Medical Center Torrance
An Open Label Non randomized Prospective Biomarker Study to Assess Analytic Concordance Between Non invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non small Cell Lung Cancer No dispute reported 06/30/2026 684989107
Principal investigator 1 TESARO, Inc. $66,906.00 01/09/2019 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689409569
Principal investigator 1 TESARO, Inc. $36,659.24 01/08/2019 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFORNIA
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689409477
Principal investigator 1 AstraZeneca UK Limited $1,000.00 01/07/2019 Non-covered Recipient Entity
Innovative Clinical Research Institute
A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN No dispute reported 06/30/2026 685000345